# Costs of non-multidrug-resistant pulmonary tuberculosis and of preventive treatment in Germany – An update

## TL;DR

This study estimates the costs of treating non-MDR tuberculosis and preventive treatment in Germany, showing a cost decrease for active TB but high costs for preventive treatment.

## Contribution

The study provides updated cost estimates for non-MDR TB treatment and TPT in Germany based on recent guidelines and insurance data.

## Key findings

- The mean inpatient cost per non-MDR TB patient was 6138 EUR, with outpatient costs significantly lower.
- Short-course TPT costs were 466 EUR for RIF alone and 423 EUR for RIF combined with Isoniazid.
- Costs for active non-MDR TB have decreased due to lower hospital reimbursement rates and increased private sector involvement.

## Abstract

Only 4076 new cases of tuberculosis (TB) were reported in Germany in 2022; of those 184 were multidrug-resistant TB (MDR-/RR-TB).

Based on the current therapy guidelines of the German Central Committee against Tuberculosis and most recent renumeration data of the Statutory Health Insurances (SHI), this study estimates the mean in- and outpatient costs per adult infectious pulmonary non-MDR-TB patient, together with costs arising from Rifampicin (RIF)-based short-course options of tuberculosis preventive treatment (TPT) of their close contacts.

From the insurance perspective, the mean inpatient cost (rounded) per adult case was 6138 EUR (SD±2810 EUR) for standard therapy; the cost of primary outpatient treatment only amounted to 1930 EUR and the cost of outpatient treatment post-hospital to 1093 EUR. The mean weighted cost was 6377 EUR (SD±2357 EUR), a drop of 27 % vs. 2019. This is mainly due to a decrease in hospitalizations of 5.6 %, and, given hospital treatment, by a 95 EUR decrease in the per-day reimbursement rate for TB patients who are hospitalized for at least 14 days. In contrast, the mean costs of TPT per person were 466 EUR (RIF solely over 4 months) and 423 EUR (RIF combined with Isoniazid over 3 months).

While costs for active non-MDR-TB treatment in Germany have clearly decreased thanks to increased engagement on the part of the private practice sector and lower reimbursement rates in hospital, the comparatively high costs of short-course TPT have surprisingly significant economic impact. This negative development can be countered through diligent selection of close contacts persons of infectious TB cases before using IGRA testing to detect latent TB, to minimize the number of those persons who are tested falsely determined to be at risk and needlessly undergo TPT.